Drug Profile
RPR 102681
Latest Information Update: 09 Jul 2002
Price :
$50
*
At a glance
- Originator Aventis
- Class Drug withdrawal therapies
- Mechanism of Action Cholecystokinin B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Substance-related disorders
Most Recent Events
- 23 Dec 1999 Rhône-Poulenc Rorer has merged with Hoechst Marion Roussel to form Aventis Pharma
- 11 Jan 1999 Phase-I clinical trials for Substance-related disorders in USA (Unknown route)